China Medical Technologies, Inc. is principally engaged in the commercialization, manufacture and sale of medical devices and supplies to customers primarily in the People鈥檚 Republic of China (the PRC). The Company develops, manufactures and markets advanced immunodiagnostic and molecular diagnostic products utilizing enhanced chemiluminescence immunoassay (ECLIA) technology, fluorescent in situ hybridization technology (FISH) technology and surface plasmon resonance (SPR) technology. Immunodiagnostic products include ECLIA analyzers and reagent kits, while molecular diagnostic products include FISH probes, SPR analyzers and surface human papillomavirus-deoxyribonucleic acid (HPV-DNA) chips (and fluorescent microscopes until April 2009). Its in-vitro diagnostics (IVD) diagnostic products are used for the detection of various cancers and other diseases and disorders. In June 2010, it established a wholly owned subsidiary, CMT Diagnostics (Singapore) Pte. Ltd.

China Medical Technologies, Inc. (the "Company") is a China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic ("IVD") products using Enhanced Chemiluminescence ("ECLIA") technology, Fluorescent in situ Hybridization ("FISH") technology and Surface Plasmon Resonance (“SPR”) technology to detect and monitor various diseases and disorders.

The Company was listed on the Nasdaq Global Select Market on August 10, 2005 and trades under the ticker "CMED". ECLIA is operated through our wholly-owned subsidiary Beijing Yuande Bio-Medical Engineering Co., Ltd. ("Yuande") in China. Yuande was established in 1999 and its headquarters and manufacturing facilities are located in the Beijing Economic-Technological Development Area. The Company was awarded ISO 9001 certification and ISO 13485:2003 certification in 2006.

Our first ECLIA analyzers and reagents were launched in 2004. In light of the Company's extensive research in chemiluminescence technology, we believe we are one of the first China-based companies to successfully develop the products and, more importantly, the first to offer an integrated platform including self-developed analyzers and reagents. We manufacture both the equipment and reagents that detect and monitor various diseases and disorders by analyzing blood through laboratory evaluation.

FISH and SPR are operated through our other wholly-owned subsidiary, Beijing GP Medical Technologies, Ltd., which was established in 2006. We acquired our FISH business in March 2007 and launched our FISH-related products in the same year. We believe the FISH products will complement our existing ECLIA diagnostic products by providing proprietary tests for the diagnosis of prenatal and postnatal disorders as well as various cancers that arise from genetic mutations.

We acquired our SPR business and HPV-DNA Biosensor Chip in October 2008. The launch of the HPV Chip is expected to address the clinical needs for HPV testing in relation to the diagnosis of cervical cancer and sexually transmitted disorder. We believe the HPV Chip will complement our FISH probes for cervical cancer diagnosis and treatment guidance. We expect the FISH and SPR acquisitions will expand and diversify our existing product portfolio and will further strengthen the Company’s leading position in the rapidly-growing area of advanced diagnostic testing in China.

China Medical Technologies is managed by an experienced team of professionals and scientists. Our dedicated research and development team is committed to the continuous development of innovative products, both internally and through collaboration with leading research institutions such as the China Academy of Science and Peking University. With an established nationwide sales and customer service network, we are well-positioned to take advantage of opportunities in both domestic and overseas markets. Our innovative products, strict quality control and comprehensive after-sales service have created a solid foundation for our continued success.